Company news
Gan & Lee Pharmaceuticals Co., Ltd. news in 2025
Gan & Lee Pharmaceuticals Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
November 17, 2025
Announcement on Positive CHMP Opinion Received for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta?)
November 13, 2025
Announcement on Resolutions of the 5th Meeting of the 5th Board of Directors
November 10, 2025
Announcement on Canceling Board of Supervisors, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Revising Some Governance Systems
October 30, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 24, 2025
Announcement on the Implementation of Repurchase and Cancellation of Partial Restricted Shares in the 2022 and 2024 Restricted Stock Incentive Plans
September 26, 2025
Announcement on the Major Contract
September 23, 2025
Announcement on Canceling Repurchased Shares and Decreasing Registered Capital and Notification to Creditors
September 7, 2025
Announcement on Results of Shareholding Reduction by Senior Management Members
August 20, 2025
Announcement on the Result of Shareholding Reduction by Shareholder and Director
August 15, 2025
Announcement on Completion of Administration of the First Subject in Phase II Clinical Trial of GZR102 Injection
August 8, 2025
Announcement on Resolutions of the 3rd Meeting of the 5th Board of Supervisors
August 7, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
August 1, 2025
Indicative Announcement on Changes in Shareholder's Equity
July 29, 2025
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
July 21, 2025
Announcement on Progress in Using Idle Raised Funds for Cash Management
July 14, 2025
Announcement on Redemption at Maturity of Idle Raised Funds Used for Cash Management
July 10, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 9, 2025
Announcement on Shareholding Reduction Plan of Shareholders, Directors and Senior Management Members
July 4, 2025
Indicative Announcement on Unlocking of the 2nd Sales Restriction Lifting Period under the 2022 Restricted Stock Incentive Plan and Unlocking and Listing of the 1st Sales Restriction Lifting Period under the 2024 Restricted Stock Incentive Plan
July 1, 2025
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
June 21, 2025
Announcement on Release of Pledge of Some Shares of Controlling Shareholder and Actual Controller
June 17, 2025
Announcement on Changing Legal Representative and Obtaining Renewed Business License
June 12, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 4, 2025
Announcement on Planning to Change Registered Capital and Amend the Articles of Association
May 30, 2025
Announcement on Electing Employee Representative Supervisor
May 20, 2025
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
March 10, 2025